Citigroup Group Ceases to Be Substantial Holder in Mayne Pharma

Mayne Pharma Group ( (AU:MYX) ) has provided an update.

Citigroup Global Markets Australia Pty Limited and its related Citi group entities have notified Mayne Pharma that they have ceased to be substantial shareholders as of 27 March 2026. The change arises from shifts in relevant interests tied to securities lending agreements, with Citigroup Global Markets Europe AG increasing and Citigroup Global Markets Limited decreasing their positions in ordinary fully paid MYX shares.

This notice signals that Citi’s overall holding in Mayne Pharma has fallen below the substantial shareholder threshold, potentially altering the company’s institutional investor mix and reducing Citi’s influence over voting outcomes. While the movements largely reflect internal reallocations within Citi’s global entities under securities lending arrangements, the exit from substantial holder status may be closely watched by other investors assessing liquidity, ownership concentration and market sentiment toward Mayne Pharma’s stock.

The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited is a pharmaceutical company listed on the ASX under the ticker MYX, specialising in the development and manufacture of generic and specialty medicines. The company operates in global markets, supplying oral and other dosage-form products to healthcare providers and distributors in Australia and internationally.

Average Trading Volume: 519,022

Technical Sentiment Signal: Sell

Current Market Cap: A$185.2M

See more insights into MYX stock on TipRanks’ Stock Analysis page.